Transcript A B Supplement 1 PCA analysis of metabolite data from untreated rice genotypes by LC-TOF and GC-TOF mass spectrometry. Top panel: (A) LC-TOF analysis of.

A
B
Supplement 1
PCA analysis of metabolite data from untreated rice genotypes by LC-TOF and GC-TOF mass
spectrometry.
Top panel: (A) LC-TOF analysis of Xa21 (black solid circles) and TP309 (gray solid circles) extracts in negative
electrospray ionization using 80 masses that were constrained by a 100% class frequency 870 threshold, i.e.
presence in 6 out of 6 biological replicates in at least one group. Bottom panel: (B) GC-TOF analysis of Xa21 and
TP309 extracts using 441 metabolites constrained by a 50% class frequency threshold
Supplement table S2.
List of all 441 metabolites positively detected by GC-TOF and ChromaTOF/BinBase data processing
in at least 50% of the samples in at least one study design class.
Each metabolite is assigned by full analytical-chemistry metadata and database identifiers.
For each compound, p-values and intensity ratios are given for pair-wise comparisons.
….
….
Supplement S3.
ANOVA for LC-TOF data comparing the three Xa21 conditions.
Using the Tukey one-way post-hoc test, the total number of statistically significant masses are given in grey blocks,
with the number of statistically significant different features (p<0.05) given in red blocks and the numbers of nondifferent features given in blues boxes.
(A) LC TOF mass spectrometry in positive ionization mode
(B ) LC TOF mass spectrometry in negative ionization mode
Supplement table S4.
Differentially expressed metabolites in pair-wise comparisons analyzed by LC-TOF MS in positive and
negative ion modes for compounds having both greater than 2-fold change and p<0.05 . Metabolites were
annotated using the METLIN personal metabolite database for a mass match (mass delta window < 5 ppm).
ESI/NEG
ESI/POS
Xa21
TP309
Xa21
raxSTPX099 PX099
vs
vs mock vs mock
mock
TP309 Xa21 Xa21
PX099 PX099 raxSTvs
vs
vs
mock mock mock
Compound Name a
Mass
RT
Formula (DB)
CAS
MFG
MS
Polarity
Alanine
89.0480
1.30
C3 H7 N O2
56-41-7
84.7
-
<2
<2
<2
<2
<2
<2
Hydroxyhydroquinone
126.0317
1.41
C6H6O3
533-73-3
83.7
+
<2
<2
<2
2.6
7.54
<2
Pyroglutamic acid*
129.0424
1.31
C5 H7 N O3
98-79-3
80.5
+
<2
<2
<2
4.7
<2
2.2
pipecolic acid*
129.0786
1.53
C6 H11 N O2
535-75-1
83.1
+
<2
<2
<2
4.2
9.6
2.6
Threonate*
136.0374
1.43
C4 H8 O5
7306-96-9
85.5
-
<2
5.4
5.14
<2
<2
<2
para-aminobenzoic acid*
137.0481
1.65
C7 H7 N O2
13115-43-0
86.5
+
<2
<2
<2
<2
<2
<2
Glutamic acid*
147.0533
1.32
C5 H9 N O4
56-86-0
84.4
+/-
<2
<2
<2
<2
<2
<2
Isoglutamine*
160.0844
1.26
C6 H12 N2 O3
7433-32-1
74.8
-
<2
<2
7.6
<2
<2
<2
Ribonic acid*
166.0480
1.39
C5 H10 O6
17812-24-7
83.8
-
<2
<2
<2
<2
<2
<2
Shikimic acid*
174.0530
1.74
C7 H10 O5
138-59-0
95.6
-
<2
0.28
0.135
<2
<2
<2
Arginine
174.1112
1.19
C6 H14 N4 O2
74-79-3
78.1
+/-
<2
<2
<2
<2
14.5
<2
Myristic acid*
228.2090
33.70
C14 H28 O2
544-63-8
95.2
-
<2
<2
<2
<2
<2
<2
1-Octadecanamine
269.3091
28.52
C18 H39 N
124-30-1
80.3
+
<2
<2
<2
<2
<2
<2
Oleamide*
281.2721
37.43
C18 H35 N O
301-02-0
98.9
+
<2
<2
<2
<2
<2
<2
Stearic acid*
284.2736
39.03
C18 H36 O2
57-11-4
92.8
-
<2
<2
<2
<2
<2
<2
Dihydrosphingosine
301.2994
25.71
C18 H39 N O2
764-22-7
78.5
+
<2
<2
<2
<2
<2
<2
Dihydromyricetin
320.0520
16.29
C15 H12 O8
27200-12-0
78.3
-
<2
<2
<2
<2
<2
<2
Amylose
324.1051
1.41
C12 H20 O10
9005-82-7
81.3
+
<2
<2
<2
<2
<2
<2
1-(5'-Phosphoribosyl)-5-amino-4imidazolecarboxamide (AICAR)
338.0639
13.59
C9 H15 N4 O8 P
3031-94-5
77.8
+/-
4.5
<2
2.2
<2
<2
<2
Sucrose*
342.1168
1.40
C12 H22 O11
57-50-1
86.3
-
0.411
<2
<2
<2
<2
<2
Adenosine monophosphate (AMP)*
347.0632
1.76
C10 H14 N5 O7 P
29706-85-2
90.3
-
<2
2.9
<2
<2
<2
<2
cis-3-(6-Hydroxy-7-methoxy-5benzofuranyl)acrylic acid glucuronide
410.0844
16.64
C18H18O11
NA
74.1
-
<2
0.043
<2
<2
<2
<2
25-hydroxy-26,27-dimethylvitamin D3*
428.3657
43.89
C29 H48 O2
NA
98.7
+
<2
<2
<2
<2
2.8
2
Myxoxanthin (Echinenone)*
550.4180
44.04
C40 H54 O
NA
98.2
+
<2
<2
<2
<2
7.6
<2
1-(9Z-heptadecenoyl)-2-(9Z,12Zheptadecadienoyl)-sn-glycerol*
590.4912
37.78
C37 H66 O5
NA
97.3
+
<2
<2
<2
<2
<2
<2
1,2-di-(9Z-heptadecenoyl)-sn-glycerol*
592.5070
38.78
C37 H68 O5
NA
69.2
+
<2
<2
<2
2.4
<2
0.39
Halocynthiaxanthin*
598.4028
32.57
C40H54O4
NA
67.5
+
<2
<2
<2
<2
12.8
11.5
Violaxanthin*
600.4183
40.25
C40 H56 O4
126-29-4
70.5
+
<2
<2
<2
0.5
<2
5.4
1-(9Z,12Z-heptadecadienoyl)-2-(9Zoctadecenoyl)-sn-glycerol*
604.5079
38.79
C38 H68 O5
NA
68.5
+
<2
<2
<2
4.3
<2
2.2
Harderoporphyrin
608.2639
37.68
C35 H36 N4 O6
NA
71.3
+
<2
<2
<2
<2
<2
<2
Rutin
610.1541
13.33
C27 H30 O16
153-18-4
98.8
+/-
0.267
4.8
5.3
0.14
<2
22.4
1,2-di-(9Z,12Z,15Z-octadecatrienoyl)-snglycerol*
612.4748
35.98
C39 H64 O5
NA
98.8
+
<2
<2
<2
<2
10.6
51.5
1-(9Z,12Z-octadecadienoyl)-2-(9Z,12Z,15Zoctadecatrienoyl)-sn-glycerol*
614.4910
36.88
C39 H66 O5
NA
97.2
+
<2
<2
<2
<2
<2
<2
1-octadecanoyl-2-(9Z,12Z,15Zoctadecatrienoyl)-sn-glycerol*
618.5225
39.84
C39 H70 O5
NA
96.7
+
<2
<2
<2
<2
<2
2.3
GPCho(12:0/13:0)*
636.4624
36.45
C33H67NO8P
NA
76.8
-
<2
2.7
<2
<2
<2
<2
GPEtn(16:0/18:2(9Z,12Z))
715.5163
45.28
C39H74NO8P
NA
67.2
+
<2
<2
<2
<2
<2
<2
GPEtn(18:2(9Z,12Z)/18:2(9Z,12Z))[U]*
739.5161
42.68
C41H74NO8P
NA
68.9
+
<2
<2
<2
2.96
<2
0.117
Chlorophyll a
892.5360
48.23
C55 H72 Mg N4 O5
479-61-8
79.5
+
<2
<2
<2
<2
<2
<2
Megalomicin B
918.5690
41.29
C46H82N2O16
NA
92.3
-
<2
<2
10.8
<2
<2
<2
a
Compounds Names with matches to METLIN database (< 5 ppm) that have >= 2-fold change between different conditions
NA: Not Available
* Other compounds can be found in the METLIN database that have the same mass (i.e. isobaric or isomeric)
Compounds having P values (P < 0.05) are shown in bold.
Fold changes are all expressed relative to the Mock condition (in the denominator)
Supplement S5.
Analysis of Rice RNA integrity measured by the Agilent 2100 Bioanalyzer.
Agilent 2100 biosizing software displays electropherogram images of total RNA samples, one
representative per group, extracted from rice leaves subsequent to metabolite extractions.
(A)
(B)
(C)
(D)
(E)
(F)
(G)
Xa21_PXO99
Xa21_NT
Xa21_Mock
Xa21_raxSTTP309_PXO99
TP309_NT
TP309_Mock.
Supplemental S6.
Table of selected significantly differentially expressed genes for three conditions:
Xa21_PXO99/Mock, Xa21_PXO99-raxST-/Mock, and TP309_PXO99/Mock.
All ratios are expressed relative to mock infection.